Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial. Jastreboff AM, Kaplan LM, Frias JP, Wu Q, et al. N Engl J Med 2023 Jun 26. doi: 10.1056/NEJMoa2301972.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Jastreboff AM, Kaplan LM, Frias JP, Wu Q, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial. N Engl J Med 2023 Jun 26. doi: 10.1056/NEJMoa2301972.
PMID: 37366315